Efgartigimod, an FcRn antagonist, as a potential treatment for post COVID-19 syndrome
A significant proportion of patients who survive coronavirus disease of 2019 (COVID-19) develop a constellation of life-altering symptoms that persist long after the initial infection has resolved. This post-COVID-19 syndrome may result from the development of autoreactive IgG antibodies that cause...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Book |
| Published: |
Compuscript Ltd,
2023-06-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Internet
Connect to this object online.3rd Floor Main Library
| Call Number: |
A1234.567 |
|---|---|
| Copy 1 | Available |